View Future GrowthBioethics 過去の業績過去 基準チェック /06Bioethicsの収益は年平均-82.1%で減少しているが、Capital Markets業界はgrowingで6.1%年平均の収益となった。主要情報-82.15%収益成長率-38.48%EPS成長率Capital Markets 業界の成長10.26%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Dec 2024最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020.収支内訳Bioethics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:BOTH 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 24000030 Sep 24000030 Jun 24000031 Mar 24000031 Dec 23000030 Sep 23000030 Jun 23000031 Mar 23000031 Dec 22000030 Sep 22000030 Jun 22000031 Mar 22000031 Dec 21000030 Sep 21000030 Jun 21000031 Mar 21000031 Dec 20000030 Sep 20000030 Jun 20000031 Mar 20000031 Dec 19000030 Sep 19000030 Jun 19000031 Mar 19000031 Dec 18000030 Sep 18000030 Jun 18000031 Mar 18000031 Dec 17000030 Sep 17000030 Jun 17000031 Mar 17000031 Dec 16000030 Sep 16000030 Jun 16000031 Mar 16000031 Dec 15000030 Sep 15000030 Jun 150000質の高い収益: BOTHは現在利益が出ていません。利益率の向上: BOTHは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BOTHの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: BOTHの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: BOTHは利益が出ていないため、過去 1 年間の収益成長をCapital Markets業界 ( 36.1% ) と比較することは困難です。株主資本利益率高いROE: BOTHの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YDiversified-financials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/10 16:38終値2025/11/13 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioethics, Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.
お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020.